Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Division of Research, Instituto Nacional de Geriatría, Mexico City, Mexico.
J Clin Endocrinol Metab. 2020 Aug 1;105(8). doi: 10.1210/clinem/dgaa346.
The SARS-CoV-2 outbreak poses a challenge to health care systems due to its high complication rates in patients with cardiometabolic diseases. Here, we identify risk factors and propose a clinical score to predict COVID-19 lethality, including specific factors for diabetes and obesity, and its role in improving risk prediction.
We obtained data of confirmed and negative COVID-19 cases and their demographic and health characteristics from the General Directorate of Epidemiology of the Mexican Ministry of Health. We investigated specific risk factors associated to COVID-19 positivity and mortality and explored the impact of diabetes and obesity on modifying COVID-19-related lethality. Finally, we built a clinical score to predict COVID-19 lethality.
Among the 177 133 subjects at the time of writing this report (May 18, 2020), we observed 51 633 subjects with SARS-CoV-2 and 5,332 deaths. Risk factors for lethality in COVID-19 include early-onset diabetes, obesity, chronic obstructive pulmonary disease, advanced age, hypertension, immunosuppression, and chronic kidney disease (CKD); we observed that obesity mediates 49.5% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes conferred an increased risk of hospitalization and obesity conferred an increased risk for intensive care unit admission and intubation. Our predictive score for COVID-19 lethality included age ≥ 65 years, diabetes, early-onset diabetes, obesity, age < 40 years, CKD, hypertension, and immunosuppression and significantly discriminates lethal from non-lethal COVID-19 cases (C-statistic = 0.823).
Here, we propose a mechanistic approach to evaluate the risk for complications and lethality attributable to COVID-19, considering the effect of obesity and diabetes in Mexico. Our score offers a clinical tool for quick determination of high-risk susceptibility patients in a first-contact scenario.
由于患有心血管代谢疾病的患者并发症发生率较高,SARS-CoV-2 疫情对医疗保健系统构成了挑战。在这里,我们确定了风险因素,并提出了一种临床评分来预测 COVID-19 的致死率,包括糖尿病和肥胖的特定因素,以及其在改善风险预测中的作用。
我们从墨西哥卫生部流行病学总局获得了确诊和阴性 COVID-19 病例及其人口统计学和健康特征的数据。我们调查了与 COVID-19 阳性和死亡率相关的特定风险因素,并探讨了糖尿病和肥胖对改变 COVID-19 相关致死率的作用。最后,我们建立了一个临床评分来预测 COVID-19 的致死率。
在撰写本报告(2020 年 5 月 18 日)时,在 177133 名受试者中,我们观察到 51633 名 SARS-CoV-2 受试者和 5332 例死亡。COVID-19 致死的危险因素包括早发性糖尿病、肥胖、慢性阻塞性肺疾病、高龄、高血压、免疫抑制和慢性肾脏病(CKD);我们观察到肥胖介导了糖尿病对 COVID-19 致死率的 49.5%影响。早发性糖尿病增加了住院的风险,肥胖增加了入住重症监护病房和插管的风险。我们用于预测 COVID-19 致死率的评分包括年龄≥65 岁、糖尿病、早发性糖尿病、肥胖、年龄<40 岁、CKD、高血压和免疫抑制,并且显著区分了致死性和非致死性 COVID-19 病例(C 统计量=0.823)。
在这里,我们提出了一种机制方法来评估归因于 COVID-19 的并发症和致死风险,考虑了肥胖和糖尿病在墨西哥的影响。我们的评分提供了一种临床工具,可在首次接触时快速确定高风险易感患者。